Company Overview and News

0
NZ shares drop on Z Energy downgrade

2018-07-18 nzherald.co.nz
New Zealand shares fell, led by Z Energy following an earnings downgrade, with Ryman Healthcare and NZX also declining.
KTHDY PGC ZNZ RHCGF RYHTY ZNRGF GTK RYM ZEL KMD KMD

0
MARKET WRAP: NZ shares fall, tech stocks gain

2018-07-16 nbr.co.nz
New Zealand shares fell below the 9000 mark today, despite a solid trading day for technology stocks and for retailer Kathmandu.
ZNZ RHCGF RYHTY ZNRGF RYM NZR ZEL

1
Brian Gaynor: KiwiSavers should surf wave of cash

2018-07-13 nzherald.co.nz
The world is awash with cash, and private equity (PE) funds are a clear example of this phenomenon.
IQE RHCGF IQE MPP RYHTY MTPGF RYM

0
NZ shares drop, led lower by Synlait Milk

2018-07-11 nzherald.co.nz
New Zealand shares dropped, led by Synlait Milk and Infratil, while Gentrack Group gained and Ryman Healthcare hit a record high.
KTHDY RHCGF RYHTY SKLUY SKL GTK RYM KMD SML KMD

0
NZ stock index rises to record

2018-07-06 nzherald.co.nz
New Zealand's benchmark stock index rose to a record, with Fletcher Building and Sky Network Television gaining while Scales and NZX dropped.
SKT FBU SYKWF RHCGF FBU FCREY RYHTY SKKTY RYM FRCEF

13
MARKET WRAP: NZ shares climb on Fletchers announcement

2018-06-21 nbr.co.nz
New Zealand shares rose today as Fletcher Building reassured its shareholders and A2 Milk played catchup.
FBU RHCGF FBU FCREY RYHTY RYM FRCEF PFGTF SML

17
Shares gain as market cheers Fletcher Building plans

2018-06-21 nzherald.co.nz
New Zealand shares rallied, pushing the S&P/NZX 50 Index to a record after Fletcher Building detailed its five-year strategy and affirmed guidance. Sky Network Television, A2 Milk, Auckland International Airport and Fisher & Paykel Healthcare rose.
AIA FBU RHCGF FCREY RYM ACKDF FRCEF AUKNY SKT SYKWF AIA PPSHY FBU RYHTY SKKTY SML

5
MARKET WRAP: NZ shares fall as US-NK summit kicks off

2018-06-12 nbr.co.nz
New Zealand shares fell slightly today, as investors and the world watched the unprecedented meeting between North Korean and American leaders unfold in Singapore.
RHCGF RYHTY RYM

13
NZ shares dip in market lull during US-North Korea summit

2018-06-12 nzherald.co.nz
New Zealand shares dipped in light trading as some stocks gave up dividends, with the focus on the US-North Korea summit in Singapore.
KTHDY SKT SYKWF RHCGF THL RYHTY SNZ SKKTY RYM KMD SML KMD

7
MARKET WRAP: NZ shares continue on record run

2018-06-11 nbr.co.nz
Harbour Asset Management analyst Shane Solly says all eyes will be on Trump’s meeting with Kim Jong Un tomorrow.
AIA RHCGF AIA RYHTY RYM ACKDF AUKNY PFGTF

15
Kathmandu leads gains as shares hit record

2018-06-08 nzherald.co.nz
New Zealand shares hit another record, rounding out the week with a 3.5 per cent gain, led higher by Kathmandu Holdings and New Zealand Refining Company.
KTHDY RHCGF AIR RYM NZR ANZFY AIZ KMD ANZLY RYHTY ANZFF KMD SML

5
MS Limited buys “too good” Box Hill HQ

2018-06-07 theage.com.au
Not-for-profit information, advice and support group, Multiple Sclerosis Limited, has paid $9.5 million for a brand new Box Hill office “too good to pass up”.
RHCGF RYHTY RYM

5
MS Limited buys “too good” Box Hill HQ

2018-06-07 smh.com.au
Not-for-profit information, advice and support group, Multiple Sclerosis Limited, has paid $9.5 million for a brand new Box Hill office “too good to pass up”.
RHCGF RYHTY RYM

15
Shares up 1% to new record, A2 and Fletcher gain

2018-06-07 nzherald.co.nz
New Zealand shares surged to a fresh record, led by A2 Milk Co and Fletcher Building amid international demand for Kiwi companies.
KTHDY AIA FBU RHCGF FCREY RYM ACKDF FRCEF AUKNY KWIPF KMD AIA FBU RYHTY KMD

13
NZX 50 rises to record, led by F&P Healthcare

2018-06-06 nzherald.co.nz
New Zealand shares rose, pushing the S&P/NZX 50 Index to a record, as Fisher & Paykel Healthcare extended its gains and investors picked up stocks that are carrying a dividend payment including Ryman Healthcare, Mainfreight and Arvida Group.
FBU RHCGF NZSTY FBU FCREY RYHTY NZSTF RYM FRCEF SML

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 006161525